
zzso is a zzso analog zzso with the intention of retaining the favorable zzso properties of zzso and zzso while eliminating their zzso zzso Phase I studies among 32 patients with acute leukemia defined a maximum tolerated dose zzso of 40 zzso given as a one hour infusion daily for 5 zzso The dose limiting toxicity zzso was transient zzso In a phase II study, 62 patients with acute zzso received zzso at the zzso over 1 hour daily for 5 zzso Twenty patients zzso achieved complete response zzso 1 had a partial response zzso and 9 had a zzso but without zzso recovery zzso for an overall response rate of zzso zzso studies in the phase I trial revealed marked zzso in peak levels of zzso among patients at the end of infusion, zzso there was a zzso dose dependent increase in zzso concentration in the zzso zzso at the zzso DNA synthesis was inhibited by more than zzso at the end of zzso In phase II studies, the relationship between the zzso of zzso zzso zzso and clinical response at the zzso was zzso revealing an zzso advantage of the zzso zzso in leukemia cells of zzso The circulating leukemia blasts of patients who respond to zzso therapy exhibited a favorable zzso zzso In conclusion, zzso is an active agent in the treatment of acute zzso and zzso and cellular zzso has zzso zzso 

